Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.

Lilly said that efsitora was equally safe and effective among adults who have previously not been on insulin therapy.

In both the studies, efsitora showed non-inferior reduction in blood sugar levels in patients, compared to the most commonly used daily long-acting insulins globally.

One of the studies also evaluated the weekly, long-acting insulin in patients who are currently using and not using GLP-1 therapies, Lilly said.